ATAZANAVIR ALPHAPHARM atazanavir (as sulfate) 150 mg capsule bottle

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

atazanavir sulfate, Quantity: 170.85 mg (Equivalent: atazanavir, Qty 150 mg)

Commercializzato da:

Alphapharm Pty Ltd

Forma farmaceutica:

Capsule

Composizione:

Excipient Ingredients: lactose monohydrate; crospovidone; magnesium stearate; titanium dioxide; brilliant blue FCF; purified water; iron oxide yellow; erythrosine; Gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; Shellac; strong ammonia solution; iron oxide black; potassium hydroxide

Via di somministrazione:

Oral

Confezione:

60

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

Atazanavir is indicated for the treatment of HIV 1 infection, in combination with other antiretroviral agents. This indication is based on analyses of plasma HIV-1 RNA levels and CD4 cell counts from controlled studies (see CLINICAL TRIALS).

Dettagli prodotto:

Visual Identification: No.1, greenish-blue opaque cap and blue opaque body, hard-shell gelatin capsule filled with white to pale yellow powder. The capsule is axially printed with MYLAN over AR150 in black ink on both the cap and body.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Stato dell'autorizzazione:

Registered

Data dell'autorizzazione:

2018-08-28